| Prof. Désiré Collen keynote speaker at the conference. |
|
He has research interests in the molecular biology and pathophysiology of haemostasis and thrombosis, the development of novel thrombolytic and antithrombotic agents, the pathogenesis and treatment of atherosclerosis, and gene targeting and gene transfer studies of the cardiovascular system. His team initially developed t-PA, currently the most effective drug for thrombolytic therapy of acute myocardial infarction. Prof. Collen has co-authored more than 620 research papers and has received four honorary doctorates (Erasmus University, Rotterdam, The Netherlands; Free University Brussels, Belgium; University of Notre Dame, IN, USA; Mediterranean University, Marseille, France) and several scientific awards including the Francqui Prize (Belgium) in 1984, the Prix Louis Jeantet de Médecine (Switzerland) in 1986, and the Bristol-Myers-Squibb award for Cardiovascular Research (USA) in 1995. Prof. Collen is Chief Executive Officer and Chairman of the Board of ThromboGenics Ltd, a biopharmaceutical drug development company in Ireland, and Chairman of the Board of its research unit Thromb-X, NV in Belgium.
|
Utrecht
December 13, 2011
December 13, 2011


July 6, 2011



